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Summary Checklist for the  
Domestic Medical Examination for Newly Arriving Refugees  
For use when screening asymptomatic refugees arriving in the United States 
 
This document presents a summary checklist for the testing suggested in the 13 sections of the 
Domestic Medical Examination for Newly Arriving Refugees. The steps outlined here do not represent 
mandatory screening requirements, but are intended as a guide to assist clinicians in performing 
a comprehensive medical evaluation. This summary checklist is for use  when screening 
asymptomatic refugees. Refugees with clinical complaints should receive diagnostic testing 




Items marked with a check box (☐) indicate “action item” components of the medical 
examination. Links are provided to the full guidelines for additional details.  
 
Medical screening should be conducted as soon as possible, and refugees should be assured ongoing 
primary care. 
 
General medical examination  
☐History and physical examination  
o Nutrition and growth  
 ☐Take dietary history (e.g., restrictions, cultural dietary norms, food allergies). 
 ☐Collect anthropometric indices, including weight, height, and, for young children, 
head circumference. 
 
o ☐Pregnancy test 
 Perform when clinically indicated prior to administration of any vaccines or medications 
which may present a risk. 
 Recommend prenatal vitamins and referral for services if test is positive. 
 
o ☐Immunizations   
 ☐Record previous vaccines, lab evidence of immunity, or history of disease. 
 ☐Give age-appropriate vaccines as indicated. Complete any series that has been 
initiated. (Do not restart a vaccine series.)   
 Doses are valid if given according to accepted ACIP or state schedules. 
 If patient has no documentation, assume he or she is not vaccinated. 
 Laboratory evidence of immunity is an acceptable alternative, as determined by 
the provider. 
 
Mental health screening 
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General laboratory testing 
☐General laboratory testing is recommended for all refugees. 
o Recommendations for all refugees  
 ☐Perform complete blood count with differential and platelets.  
 ☐ Conduct urinalysis (optional in persons unable to provide a clean-catch specimen).  
 ☐Consider testing  glucose and serum chemistries.  
 
o Recommendations for infants  
 ☐Conduct infant metabolic screening for newborns, according to state guidelines.  
 
☐Disease-specific laboratory testing  
o ☐Tuberculosis   
 ☐Review overseas records. 
 ☐Evaluate for signs or symptoms of disease, history of contacts,  and physical 
examination (low threshold for evaluation). 
 ☐Conduct a Tuberculin Skin Test or IGRA. (Use of IGRA in children < 5 years of age 
is not encouraged.)  
 ☐For a positive screening test, perform  chest x-ray and sputum testing as 
indicated. 
 
o ☐Lead testing  
 ☐Screen all refugee children 6 months to 16 years of age.  
 ☐Conduct an additional lead test on all children aged 6 months - 6 years within 3-6 
months of placement in a permanent residence, regardless of the results of the initial lead 
test. 
 
o ☐Malaria  
Note: All sub-Saharan African (SSA) refugees who arrived from countries that are endemic 
for Plasmodium falciparum and who do not have a contraindication should be assumed to 
have received pre-departure presumptive antimalarial therapy with artesunate-combination 
therapy (ACT). 
 Refugees who require post-arrival testing or presumptive treatment include the following: 
(The most sensitive test for persons with sub-clinical malaria is polymerase chain 
reaction (PCR); when PCR is not available, traditional blood films and/or a rapid antigen 
test may be used but have limited sensitivity in asymptomatic persons.) 
 SSA refugees receiving no presumptive treatment prior to departure.  This 
includes any pregnant or lactating women, or children weighing less than 5 kg at 
the time of departure, for whom presumptive treatment was contraindicated. 
 Any refugee from a malaria-endemic country with signs or symptoms of infection 
should receive a thorough evaluation.  
 Refugees not requiring post-arrival testing or presumptive treatment include the 
following: 
 SSA refugees receiving presumptive treatment prior to departure. 
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o ☐ Intestinal and Tissue Invasive Parasites (ITIP)  
 Notes:  
 Post-arrival screening for invasive parasites (IP) will depend on the region of departure and 
pre-departure presumptive therapy received.  
 Currently, all refugees without contraindications from the Middle East, South and Southeast 
Asia, and Africa receive a single dose of albendazole prior to departure.  In addition, all SSA 
refugees without contraindications receive treatment with praziquantel for schistosomiasis.  
The only population currently receiving presumptive therapy for strongyloides is Burmese 
refugees, who receive ivermectin if they do not have contraindications. 
 
For those who have contraindications or who did not receive complete pre-departure therapy, 
the following ITIP screening is recommended: 
 For refugees who had no pre-departure presumptive treatment (Figure 1):  
 ☐Roundworms/nematodes (all refugees):  Conduct stool ova and parasites 
examination (2 or more samples) or provide presumptive treatment. 
 ☐Strongyloides (all refugees):  Provide presumptive therapy or conduct 
diagnostics for Strongyloides (e.g., serologies for strongyloides, 2 or more stool 
ova and parasites examinations, and/or Strongyloides culture/agar method). 
 ☐Schistosomiasis (SSA refugees):  Provide presumptive therapy or conduct 
serologies for schistosomiasis (for SSA refugees who did not receive 
praziquantel).   
 ☐Absolute eosinophil count (routinely recommended as part of the hematology 
testing and is not sensitive or specific for invasive parasites; however, a 
persistently elevated count indicates the need for further investigation). 
 For refugees who received incomplete presumptive treatment (Figure 2):  
  ☐Strongyloides (all refugees):  Provide presumptive therapy or conduct 
diagnostics for Strongyloides (e.g., serologies for strongyloides, 2 or more stool 
ova and parasites examinations, and/or Strongyloides culture/agar method).  
 ☐Schistosomiasis:  Provide presumptive therapy or conduct serologies for 
schistosomiasis (SSA refugees who did not receive praziquantel).   
 ☐Absolute eosinophil count (routinely recommended as part of the hematology 
testing and is not sensitive or specific for invasive parasites; however, a 
persistently elevated count indicates the need for further investigation). 
 For refugees who received complete pre-departure presumptive treatment: 
 ☐Absolute eosinophil count (routinely recommended as part of the hematology 
testing and is not sensitive or specific for invasive parasites; however, a 
persistently elevated count indicates the need for further investigation) (Figure 3). 
 
o ☐Sexually transmitted diseases   
Obtain history for signs and symptoms and conduct physical examination. 
 Syphilis  
 ☐If no documentation, obtain VDRL (venereal disease research laboratory) 
or RPR (rapid plasma regain) for the following: 
 All refugees  > 15 years old 
 Refugees < 15 years old if 
 sexually active or history of sexual abuse               
 mother who tests or tested positive                      
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 exposure in a country endemic for other treponemal subspecies (e.g., 
yaws, bejal, pinta).  
 ☐Conduct confirmation testing for positive treponemal tests. 
 
  Chlamydia  
 ☐Conduct a urine nucleic amplification test for the following: 
 Women < 25 years old who are sexually active 
 Women > 25 years old with risk factors (e.g., new or multiple partners)                  
 Leucoesterase (LE) positive on urine sample                              
 Women or children with history of or at risk for sexual assault 
 Any refugee with symptoms 
 
 Gonorrhea  
 ☐Conduct a urine nucleic amplification test for the following: 
 Leucoesterase (LE) positive on urine sample 
 Women or children with history of or at risk for sexual assault 
 Any refugee with symptoms 
 
 ☐HIV   
As of January 4, 2010, refugees are no longer tested for HIV infection prior to arrival 
in the United States. 
 ☐All refugees should be screened unless they opt out. Refugees should be clearly 
informed orally or in writing when/if they will be tested for HIV. A refugee’s 
decision to decline an HIV test should be documented in the medical record. 
 ☐Screening should be repeated 3-6 months following resettlement for 
refugees who had recent exposure or are at high risk.  
 ☐Provide culturally sensitive and appropriate counseling for all HIV-infected 
refugees in their primary spoken language, and ensure the competence of 
interpreters and bilingual staff to provide language assistance to patients with 
limited English proficiency. 
 ☐Refer all refugees confirmed to be HIV-infected for care, treatment, and 
preventive services. 
 Special considerations for children:  
 ☐Screen children <12 years of age unless the mother’s HIV status can 
be confirmed as negative and the child is otherwise thought to be at low 
risk of infection (no history of high-risk exposures such as blood product 
transfusions, early sexual activity, or sexual abuse). In most situations, 
complete risk information will not be available; thus, most children <12 
years of age should be screened. 
 ☐For children <18 months of age, who test positive for HIV antibodies, 
test with DNA or RNA assays. Results of positive antibody tests in this 
age group can be unreliable because they may detect persistent maternal 
antibodies. 
 ☐ Provide chemoprophylactic trimethoprim/sulfamethoxazole for all 
children born to or breast-fed by an HIV-infected mother, beginning at 6 
weeks of age and continuing until they are confirmed to be uninfected.  
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 Special considerations for pregnant women:  
 ☐ Screen all pregnant refugee women as part of their routine post arrival 
and prenatal medical screening and care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
